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Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes
right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like
factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal
microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular
remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators
of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced,
while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heri-
table PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-
5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells
and attenuates disease progression in PAH mice. This study shows that reduced
KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic
role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular
remodelling.
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Pulmonary arterial hypertension (PAH) is a severe lungdisorder characterised by progressive vascular remodellingand increased vasoconstriction. Endothelial damage fol-
lowed by proliferation of vascular endothelial and smooth muscle
cells underlie the disease pathology1 and hypoxia and inflam-
mation are known contributory factors2. Formation of angio-
obliterative vascular lesions, driven by vascular endothelial
growth factor (VEGF), is a hallmark of severe PAH3.
Recently, a missense mutation in the transcription factor
Krüppel-like factor 2 (KLF2) gene was identified in a family with
autosomal heritable pulmonary arterial hypertension (HPAH),
suggesting that KLF2 signalling may be compromised in the
disease4.
KLF2 is activated by shear stress and plays a key role in the
regulation of lung function and development5. KLF2-null mice
exhibit abnormal blood vessel formation, resulting in embryonic
haemorrhage and death. Within the blood vessel wall, KLF2 is
exclusively expressed in endothelial cells and promotes vascular
homoeostasis, counteracting inflammation, vascular leakage,
thrombosis and VEGF-induced angiogenesis. KLF2 also inhibits
endothelial cell apoptosis while promoting metabolic quiescence
and reducing metabolic dependence on glucose6. The identifica-
tion of a missense mutation in KLF2 gene is significant, as
accumulating evidence from pre-clinical models of PAH impli-
cates reduced KLF2 signalling in PAH pathogenesis. Inhibition of
KLF2 expression correlates with increased severity of pulmonary
hypertension (PH) in apelin knockout mice exposed to hypoxia7.
KLF2 overexpression improves pulmonary haemodynamics in
hypoxic rats8, but can impair liver function9,10, so other ther-
apeutic approaches need to be identified.
microRNAs (miRNAs) are small (~22 nucleotide long) non-
coding RNAs that negatively regulate gene expression at the
posttranscriptional level11. Recent studies have shown that miR-
NAs released by the cells in exosomes, small membrane vesicles
of 40–100 nm in diameter, can be taken up and modulate reci-
pient cell responses in the immediate neighbourhood as well as in
distant organs and tissues12,13.
Dysregulation of several miRNAs has been demonstrated in
human and animal PAH but the choice of which miRNAs to
target constitutes a conceptual challenge14. For example, the levels
of KLF2-dependent miR-150 in plasma exosomes from PAH
patients are reduced and correlate with survival15. Pioneering
work by Hergenreider et al.16 demonstrated that exosome-
mediated transfer of miRNAs from KLF2-overexpressing endo-
thelial cells to underlying vascular SMCs reduces SMC de-differ-
entiation, thus representing a strategy to combat atherosclerosis16.
Exosomes have gained special interest as carriers of miRNAs
because of their transportability and the ability to convey infor-
mation within the circulatory system12. However, the complexity
of the exosomal cargo and low production yield are obstacles for
clinical translation17.
Our approach was to determine whether exosomal miRNAs
from KLF2-overexpressing endothelial cells have vasculoprotec-
tive effects in PAH. We demonstrate dysregulation of KLF2-
induced miRNA signalling in endothelial cells and lung tissues
from idiopathic PAH (IPAH) patients and heritable PAH patients
with a KLF2 mutation and present evidence of homoeostatic and
anti-remodelling effects of KLF2-induced miR-181a-5p and miR-
324-5p in vitro and in vivo.
Results
Endothelial exosomes mimic homoeostatic effects of KLF2. In
order to study the effects of KLF2-induced exosomes, KLF2 was
overexpressed in human pulmonary artery endothelial cells
(HPAECs) via adenoviral gene transfer. Recombinant KLF2 showed
nuclear localisation (Fig. 1a) and the level of KLF2 overexpression
(~3-fold increase) corresponded to the expression level induced
by physiological shear stress (10 dynes/cm2) in medium-size pul-
monary arteries18.
Exosomes were isolated from conditioned media collected from
control (AdGFP) and AdKLF2-GFP-overexpressing (AdKLF2)
HPAECs and the purity of the obtained fraction was confirmed
by Nanosight LM10 particle tracking and exosomal protein marker
analysis (Supplementary Fig. 1a–f). Conditioned media contained
predominantly exosome-sized (<100 nm in diameter) particles, with
approximately ~2 × 1010 particles in each mL of medium. No
significant differences in the total exosome number were found
among the groups (Supplementary Fig. 1c, d). Purified exosomes
were added to the cultured HPAECs at 1:1 donor-to-recipient cell
ratio, i.e. exosomes produced by 10 KLF2-overexpressing cells were
added to 10 recipient cells in culture, corresponding to ~105
particles per cell. Internalisation of fluorescently labelled exosomes
was evident after 1 h of incubation (Fig. 1b). Small numbers of
adenoviral particles (~100 pfu/mL) detected in the purified
concentrated exosomal fractions had no impact on KLF2 expression
in exosome-treated cells (Supplementary Fig. 2). Transmission
electron microscopy of adenovirus-infected HPAECs revealed that
virions localised to cell nuclei and were absent in cytoplasmic
vesicular structures (Supplementary Fig. 3), suggesting that the viral
contaminants may have originated from damaged cells.
Treatment of HPAECs with KLF2 exosomes attenuated
apoptosis and reduced hypoxia- and TNF-α-induced activation
of the pro-inflammatory transcription factor NFκB (Fig. 1c, d).
KLF2 exosomes also inhibited VEGF-induced proliferation
(Fig. 1e, Supplementary Fig. 4) in HPAECs, mimicking to a
large extent the effects induced by KLF2 overexpression
(Fig. 1f–h). Treatment of cells with control (AdGFP) adeno-
viruses or control exosomes had no significant effect on cell
responses to proliferative or inflammatory stimuli (Supplemen-
tary Fig. 5).
The transcription factor KLF4 shows functional overlap with
KLF219 and its deletion from endothelium exacerbates PH in
hypoxic mice20. KLF4 silencing did not affect exosome-induced
responses or KLF2 expression in cells (Supplementary Fig. 6),
suggesting that the observed effects were KLF4 independent.
Exosomes have been administered therapeutically in several
disease models. Intravenously injected exosomes can be taken up
by the vascular endothelium and underlying vascular tissues21.
Consistently, we observed localisation of fluorescently labelled
endothelial exosomes in the vasculature of different organs in mice
4 h after injection (Supplementary Fig. 7). Of the cargo that
exosomes carry, miRNAs have attracted most interest in terms of
their functional and therapeutic importance22. We therefore carried
out an unbiased screen of KLF2-induced exosomal miRNAs with
the view of establishing a more viable treatment strategy.
Selection of potentially therapeutic exosomal miRNAs. miRNA
profiling was carried out with miRCURY LNATM Universal RT
microRNA PCR (Human panel I+II) on exosome fractions from
control (AdGFP) HPAECs and KLF2-overexpressing (AdKLF2)
HPAECs. Three hundred and thirty miRNAs were detected per
sample, with 183 miRNAs shared among all samples and 110
miRNAs differentially expressed using a cut off P value < 0.05.
Eighty-six of these miRNAs passed a Benjamini–Hochberg cor-
rection (P-adj < 0.05) (Supplementary Table 1). A heat map with
unsupervised hierarchical clustering performed on the 86 differ-
entially expressed miRNAs is shown in Fig. 2.
The list of exosomal KLF2 miRNAs was then compared with
published lists of miRNAs differentially expressed in human PAH
and chronic hypoxia and MCT rat models of PAH15,23. Eight
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14966-x
2 NATURE COMMUNICATIONS | (2020)11:1185 | https://doi.org/10.1038/s41467-020-14966-x | www.nature.com/naturecommunications
miRNAs increased by KLF2 but reduced in human or animal
PAH were selected for further studies. The selected miRNAs
comprised of let-7a-5p, miR-10a-5p, miR-125b-5p, miR-181a-5p,
miR-191-5p, miR-30a-3p, miR-30c-5p, and miR-324-5p (Supple-
mentary Table 2).
Exosomes and miRNAs can be transferred between cells at a
distance24. To verify whether miRNAs can pass from cell to cell
under flow conditions, HPAECs were cultured in Ibidi flow
chambers connected in tandem (Supplementary Fig. 8). The cells
grown in the first chamber were transfected with fluorescent
Cy3-miR and then the unbound probe was washed away before
the onset of flow typical for proximal pulmonary arterioles18, at
4–10 dynes/cm2. The results show a directional transfer of
fluorescent miRNA between endothelial cells under physiological
range flow (Supplementary Fig. 8).
Endothelium-protective effects of miR-181 and miR-324. To
verify the role of the eight selected exosomal miRNAs, HPAECs
were transfected with miRNA mimics prior to starvation, hypoxic
exposure or stimulation of cells with TNF-α. Transfection effi-
ciency, evaluated with Cy3-labelled miRNA, was ~80 ± 5%.
Only miR-181a-5p and miR-324-5p (referred in the manuscript
as miR-181 and miR-324), were protective in all study conditions
(Supplementary Fig. 9) and were therefore chosen for further
analysis. Interestingly, while single treatments had only partial
effect, the combined treatment with miR-181 and miR-324 was
significantly more potent (Fig. 3a–d). To see if miR-181 and miR-
324 mediate the protective actions of KLF2 exosomes, the exosome-
producing cells were transfected with specific miRNA inhibitors.
This resulted in a complete inhibition of the endothelium-protective


































































































































































































































































































































Fig. 1 Effect of KLF2 and KLF2-induced exosomes on endothelial cell apoptosis, inflammatory activation and proliferation. a Expression of KLF2 in
cells infected with AdGFP and AdKLF2-GFP (24 h). Infected cells are green and the arrowhead points to nuclear localisation of KLF2; bar= 10 µm.
b Internalisation of PKH26 Red-labelled exosomes (arrowheads) 1 h after treatment. Bar= 2 µm. Effects of c–e KLF2-induced exosomes and KLF2 (f–h) on
caspase 3 per 7 activation in serum-starved HPAECs (24 h), hypoxia- and TNF-α-induced (10 µg/L, 24 h) NFκB activation and VEGF-induced (50 ng/mL,
18 h) cell proliferation in HPAECs, as indicated. Control exosomes were purified from AdGFP-expressing cells, while KLF2 exosomes were purified from
AdKLF2-overexpressing HPAECs. **P < 0.01; ***P < 0.001, ****P < 0.0001 comparison with Adcontrol. #P < 0.05, ##P < 0.01, ####P < 0.0001 comparison
with treatment controls. One-way ANOVA with Tukey post-test. Values in c–h are mean fold-changes of Adcontrols ± s.e.m. In c n= 4, d n= 6–7, e n=
6–8, f n= 7, g n= 4–6 and h n= 6 of independent experiments. Source data are provided in Source Data file.
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miR-181 and miR-324 levels were significantly elevated in
KLF2 exosomes and KLF2-overexpressing cells, while the levels of
miR-32 were reduced (Supplementary Table 1, Supplementary
Fig. 11). Cells treated with KLF2 exosomes showed a significant
increase in miR-181 and miR-324 content (Fig. 3e, f). The export
ratio (the ratio between the exosomal and the intracellular levels
of miRNA) was 1.37 for miR-181a-5p and 1.40 for miR-324-5p,
indicating that these miRNAs are actively exported by the cells
(Fig. 3g). Expression levels of KLF2, miR-181 and miR-324 were
also markedly elevated in flow-stimulated HPAECs (Fig. 3h–j).
To see if miR-181 and miR-324 play a role in endothelial-to-
smooth muscle cell communication, human pulmonary artery
smooth muscle cells (HPASMCs) were co-cultured with KLF2-
overexpressing HPAECs in Transwell dishes. The two cell types
were separated by a porous membrane (Fig. 4a), which allows
exchange of exosomal particles16. HPASMCs co-cultured with
KLF2-overexpressing HPAECs showed elevated intracellular levels
of miR-181 and miR-324 (Fig. 4b, c), while intracellular levels of
KLF2 remained unchanged (Supplementary Fig. 12a). PASMCs
showed reduced hypoxia- and PDGF-induced cell proliferation
(Fig. 4d, e), which was prevented by miR-181 and miR-324
inhibitors and the exosome release inhibitor, GW486925 (Fig. 4d, e).
In contrast to the effects induced by endothelial KLF2 exosomes,
direct overexpression of KLF2 did not abrogate PDGF-induced
HPASMC proliferation (Supplementary Fig. 12b, c), indicating that
KLF2 effects are cell-type specific26.
RNA profiling in miR-181 and miR-324-overexpressing HPAECs.
HPAECs transfected with miR-181, miR-324 or non-targeting
control miRNA were subjected to RNA profiling to identify targets
of potential therapeutic significance. Pairwise differential expression
analysis was performed based on a model using the negative bino-
mial distribution and P values were adjusted for multiple test cor-
rection using the Benjamini–Hochberg procedure27.
The list of transcripts that were downregulated by miR-181 and




























































































Fig. 2 KLF2-induced changes in exosomal miRNA expression. a Heat map and unsupervised hierarchical clustering. The clustering was performed on
three samples of exosomal pellets collected 24 h post-infection with AdGFP or AdKLF2-GFP. Each row represents one miRNA, and each column represents
one sample. The miRNA clustering tree is shown on the left. The colour scale illustrates the relative expression level of an miRNA across all samples: yellow
colour represents an expression level above mean and purple colour represents expression lower than the mean.
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for miR-181 and 930 for miR-324) and up-regulated (240 for miR-
181 and 251 for miR-324) was compared with the list of predicted
in silico target genes. miR-181- and miR-324-mediated targeting
of specific mRNAs, including ETS-1 and Notch4 was confirmed
by qPCR and luciferase reporter assays (Supplementary Figs. 13
and 14). Thirty-six target genes of miR-181 and 37 target genes of
miR-324 were then selected for pathway enrichment analysis
(Fig. 5a, Supplementary Fig. 15 and Supplementary Tables 3 and
4). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway enrichment analysis of targets down-
regulated by miR-181 and miR-324 showed significant associa-
tions with TNF-α (P-adj= 2.41 × 10−6, Fisher’s exact test with
false discovery rate correction), MAPK (P-adj= 3.6 × 10−4),
NFκB (P-adj= 1.1 × 10−4), VEGF (P-adj= 1.32 × 10−2), and
Toll-like receptor signalling pathways (P-adj= 1.2 × 10−4; Fig. 5b
and Table S5 in the Online Data Supplement). Heat maps and
unsupervised hierarchical clustering are shown in Fig. 5c. Key
targets of miR-181a-5p associated with inflammation, cell
proliferation and vascular remodelling included α-SMA, TNF-α,
IL-1, Notch4 and MMP10, while targets of miR-324-5p included
MAPK, NFATC2 and ETS-1 (Supplementary Table 5). No
significant KEGG pathway associations were found for targets
up-regulated by miR-181 and miR-324.
KLF2, miR-181 and miR-324 and their target genes in PAH.













































































































































































































































































































































































































Fig. 3 miR-181 and miR-324 mediate endothelium-protective effects of KLF2 exosomes. a Anti-apoptotic, b, c anti-inflammatory and d anti-proliferative
effects of single and combined treatments with miR-181 and miR-324. HPAECs transfected with specific miRNAs were serum-starved or were infected
with AdNFκB-luc and stimulated with hypoxia or TNF-α (10 µg/L) for 24 h. Alternatively, HPAECc grown in serum-reduced medium were treated with
VEGF (50 ng/mL, 18 h). emiR-181 and fmiR-324 levels in HPAECs incubated with control or KLF2 exosomes for 24 h; qPCR. g Export ratios for miR-181and
miR-324. h KLF2 mRNA, i miR-181 and j miR-324 changes in HPAECs under flow (10 dynes/cm2, 24 h). Bars show mean fold change of untreated
controls ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, comparison with transfection controls; #P < 0.05, #P < 0.05, ###P < 0.001,####P <
0.0001, comparison with treatment controls or as indicated; &P < 0.05, &&P < 0.01, comparisons as indicated. One-way ANOVA with Tukey post-test (a–d)
and unpaired t-test (e–j). In a n= 4–6, b n= 4–8, c n= 4–12, d n= 6–7, e–j n= 3 of independent experiments. Source data are provided in Source Data file.
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used as surrogates for pulmonary endothelial cells in PAH. We
examined the levels of KLF2, miR-181 and miR-324 and their
selected gene targets in ECFCs from healthy volunteers (n= 14)
and IPAH patients (n= 12). The IPAH cells showed a significant
reduction in KLF2 mRNA, miR-181 and miR-324 and a marked
increase in the levels of Notch4 (target of miR-181) and ETS-1
(target of miR-324) mRNAs, compared with healthy controls
(Fig. 6 a–e).
Notch4 and ETS-1 are key regulators of endothelial prolifera-
tion and angiogenesis. Consistent with the elevated levels of
Notch4 and ETS-1, IPAH ECFCs showed increased proliferation
and tube formation in Matrigel compared with healthy controls
(Fig. 6f–h). These responses were markedly reduced in cells
transfected with either miR-181 and miR-324 or ETS-1 and
Notch4 siRNA (Fig. 6f, h). Reduction in ETS-1 and Notch4
expression in siRNA-transfected cells was confirmed by qPCR
(Supplementary Fig. 16).
The RNAscope fluorescent in situ hybridisation, which allows
specific identification and quantification of single transcripts28,
showed a marked reduction in the endothelial KLF2 mRNA and
increased expression of Notch4 and ETS-1 mRNA in the
remodelled vasculature of IPAH patients, compared with healthy
lungs (n= 6 per group) (Fig. 7a–e). Similar changes in KLF2,
ETS-1 and Notch4 protein expression were noted in lung lysates
from IPAH patients, compared with controls (Supplementary
Fig. 17).
HPAH patients with c-terminal (p.H288Y) KLF2 mutation
(n= 3) also showed a marked upregulation of Notch4 and ETS-1
in the remodelled pulmonary vasculature, identified by endothe-
lial vWF and a prominent α-SMA staining in the small, normally
non-muscularised arterioles (Fig. 7f–i). p.H288Y is a hetero-
zygous germline mutation that results in a missense substitution
of histidine at amino acid position 288 by arginine in the c-
terminal zinc-finger protein domain of KLF2, which has been
described as a recurrent somatic mutation in B cell lymphoma4,29.
Loss of function caused by this mutation in HPAECs was
confirmed by reduced nuclear localisation of the p.H288Y
(c.862C>T) KLF2 mutant and a loss of anti-proliferative and
anti-inflammatory effect in vitro (Supplementary Fig. 18).
miR-181 and miR-324 supplementation attenuates PH in mice.
As a proof-of-concept, the Sugen/hypoxia mouse model of PAH
was employed to study changes in the expression of KLF2 and
miR-181 and miR-324 target genes in the remodelled lung, and to
evaluate therapeutic potential of miR-181 and miR-324. In this















































































































































































































































Fig. 4 The effect of endothelial KLF2 on smooth muscle cell proliferation. a Transwell dish with KLF2-overexpressing HPAECs separated from HPASMCs
by a porous (0.4 µm pore size) membrane. b, c miR-181 and miR-324 levels in HPASMCs co-cultured with Adcontrol and AdKLF2-overexpressing HPAECs
for 24 h. The effect of endothelial KLF2 exosomes on d PDGF (10 ng/mL, 48 h) and e hypoxia-induced HPASMC proliferation. HPAECs pre-treated
with exosome inhibitor GW4869 (10 µM) were used as a negative control. In d, e, bars show the percentage of untreated, untransfected controls;
*P < 0.05, **P < 0.01, ***P < 0.001, comparison with Adcontrol or exosomes group; ###P < 0.001, comparison with Adcontrol+exosomes, hypoxia group;
#P < 0.05; &P < 0.05, comparisons as indicated. Unpaired t-test (b, c) or one-way ANOVA with Tukey post-test (d, e). Bars are means ± s.e.m. (b, c) n= 5,
d n= 3–5, e n= 5–12 of independent experiments. Source data are provided in Source Data file.
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an exaggerated vascular repair, driven largely by VEGF signalling,
which further increases disease severity3.
Pilot experiments confirmed the enhanced effect of combined
treatment (Supplementary Fig. 19). Three-week exposure to Sugen/
hypoxia induced a significant increase in the right ventricular
systolic pressure (RVSP), right ventricular hypertrophy (RVH) and
pulmonary vascular muscularisation in mice (Fig. 8a–c, h).
Intravenous administration of miR-181 and miR-324 resulted in
a significant increase in the levels of these miRNAs in the lungs of
treated mice (Supplementary Fig. 19). RVSP, RVH and vascular
muscularization were significantly reduced in animals treated with
miR-181 and miR-324 (Fig. 8a–h).
The levels of KLF2 mRNA in the lungs of PH mice were
significantly lower compared with the lungs of healthy mice
(Fig. 8d). Changes in mouse body weight are shown in Supple-
mentary Fig. 20.
A marked reduction in KLF2 mRNA seen in the pulmonary
vascular endothelium of Sugen/hypoxia mice was accompanied by
increased expression of Notch4 and ETS-1 mRNA (Fig. 8e–j).

























































































































































































(P-adj < 0.01 )
Filtering by fold-change
–1.5 > X > 1.5
Downregulated genes
Prediction insilico
Fig. 5 Identification of miR-181 and miR-324 targets using RNA sequencing and pathway analysis. a Flow chart shows identification of potential miRNA
targets in PAH. HPAECs were transfected with miRNA mimics and subjected to RNA sequencing. Pairwise differential expression analysis was performed
based on a model using the negative binomial distribution and P values were adjusted for multiple test correction using the Benjamini–Hochberg procedure;
*P < 0.05, **P < 0.01. miRNA target prediction was carried out with TargetScan Human, miRecords and Ingenuity Expert Findings (IPA). b Gene enrichment
(GO pathways, Panther) in HPAECs transfected with miR-181 and miR-324. c Heat map and unsupervised hierarchical clustering. The clustering was
performed on two control samples (HPAECs transfected with miRNA control) and two samples of HPAECs transfected either with miR-181 or miR-324.
Yellow colour represents an expression level above mean and purple colour represents expression lower than the mean.
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Fig. 6 Dysregulation of KLF2 signalling in ECFCs from IPAH patients. a KLF2 mRNA, bmiR-181 and cmiR-324, d ETS-1 and e Notch4 expression in ECFCs
from healthy volunteers (n= 14) and IPAH patients (n= 12). f, g Proliferation (EdU incorporation) and h angiogenesis (matrigel tube formation) in ECFCs
from healthy individuals and IPAH patients, transfected with control miRNA, control siRNA, miR-181 and miR-324 or Notch4 and ETS-1 siRNA, as indicated.
Representative corresponding images of tube formation in fluorescently labelled live ECFCs are shown underneath the graph. In g EdU-incorporating nuclei
are pink. In g bar= 20 µm and in h bar= 100 µm; *P < 0.05, **P < 0.001, comparison with corresponding controls; #P < 0.05, ##P < 0.01, comparison
between controls and miR-181 and miR-324- or ETS-1 and Notch4-treated IPAH ECFCs. Bars are means ± s.e.m. In a–e n= 12–14, unpaired t-test and in f, h
n= 4–8, one-way ANOVA with Tukey post-test. All n numbers are biologically independent samples. Source data are provided in Source Data file.
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Fig. 7 KLF2, ETS-1 and Notch4 mRNA levels in lung tissues of PAH patients. a Representative images of KLF2, ETS-1 and Notch4 mRNA distribution in
healthy and PAH lung; RNAscope fluorescent in situ hybridisation. b α-SMA and vWF staining in healthy and PAH lung. In a, b, bar= 50 µm. c–e Graphs
showing KLF2, ETS-1, and Notch4 mRNA levels in healthy and PAH lung tissues; n= 6. f Representative images of ETS-1 and Notch4 mRNA expression in
healthy lung and lungs from HPAH patients with disabling KLF2 mutation. g α-SMA and vWF staining in healthy and HPAH lung. In f, g bar= 25 µm.
h, i graphs showing ETS-1 and Notch4 levels in healthy lung tissues and lung tissues from HPAH patients with KLF2 mutation, n= 3. In c–i values are mean
fold-changes of controls ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, comparison with healthy controls; unpaired t-test. All n numbers are biologically
independent samples. Source data are provided in Source Data file.
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Fig. 8 Delivery of miR181 and miR-324 attenuates pulmonary hypertension and reduces expression of Notch4, ETS-1 and NFκB activity in Sugen/
hypoxia mice. a Right ventricular hypertrophy (RV/LV+S), b RVSP, and c vascular muscularisation in mice treated, as indicated. Changes in d KLF2,
e ETS-1, f Notch4 mRNA levels, and g NFκB activity (nuclear localisation) in the lungs of Sugen/hypoxia mice; fluorescence (arbitrary units). **P < 0.01,
***P < 0.001, ****P < 0.0001, comparison with untreated controls; #P < 0.05, ##P < 0.01, ###P < 0.001, comparisons as indicated. Values are means ± s.e.m.
One-way ANOVA with Tukey post-test. h Representative images of α-SMA staining in the untreated and miR-181+miR-324-treated mice lungs. i Co-
localisation of KLF2 mRNA with vWF in mouse lung endothelium. j KLF2, ETS-1, Notch4 mRNA and nuclei in lung endothelial cells from healthy, pulmonary
hypertensive (PH) and miRNA-treated mice, as indicated. Fluorescent in situ hybridisation, confocal microscopy. Each fluorescent dot corresponds to a
single transcript; arrowheads point to endothelial cells. In h, i bar= 25 µm and in j bar= 10 µm. In a n= 8, b n= 6–7, c n= 6–8, d n= 7–8, e n= 6–8, f n=
7–8, g n= 8 of biologically independent samples. Source data are provided in Source Data file.
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resulted in a decrease in the mRNA and protein expression of
Notch4 and ETS-1 and α-SMA, reduction in NFκB activity and
reduction in the expression of cell proliferation marker, PCNA, in
the lung (Fig. 8e–j, Supplementary Figs. 21–24). Interestingly,
endothelial KLF2 mRNA expression was partially restored in
miRNA-treated mice, possibly as a result of improved flow
conditions, secondary to the reduction in vascular remodelling
(Fig. 8d–j, Supplementary Fig. 21). Endothelial localisation of the
transcripts was confirmed by co-staining with vWF (Fig. 8i).
Discussion
We are first to provide evidence that KLF2 signalling is a com-
mon feature of human PAH and describe therapeutic, cooperative
actions of KLF2-induced endothelial miRNAs involving key
regulators of vascular homoeostasis, Notch4 and ETS1.
Data from pre-clinical studies and discovery of a missense
mutation in KLF2 gene in human HPAH suggest that KLF2
function may be compromised in PAH. While viral delivery of
KLF230 or treatment with KLF2-induced exosomes13,16,31 can
offset some of the effects of KLF2 inhibition, they have limited
applicability in clinical practice17,32. We sought to determine
whether exosomal miRNAs released by KLF2-overexpressing
endothelial cells have a vasculo-protective effect in PAH. We
show that delivery of selected KLF2-induced exosomal miRNAs
improves pulmonary endothelial cell survival, reduces inflam-
matory responses and restricts vascular cell proliferation in vitro
and in vivo.
To identify mediators of these effects, we conducted an
unbiased screen of exosomal miRNAs and selected eight miRNAs
of interest, which were upregulated by KLF2 but reduced in PAH,
with the view of potential therapeutic intervention. Of these, only
miR-181 and miR-324 were protective in all experimental con-
ditions and their effects were enhanced by combined treatment.
Functional convergence of multiple miRNAs on disease-relevant
pathways has been demonstrated in the prevention of cardiac
dysfunction and cancer14,33–35. miR-181 and miR-324 targets
showed significant associations with key regulatory pathways in
PAH, including TNF-α, MAPK, VEGF, NFκB, Toll-like receptor
and N-acetylglucosamine (GlcNac) signalling. Numerous func-
tional links among their respective gene targets may explain, at
least in part, their synergistic effects observed in vitro and in vivo.
The miR-181 family suppress NF-κB signalling and regulate
endothelial cell activation, proliferation and immune cell homo-
eostasis36. Specifically, miR-181a-5p downregulates TNF-α, the
key mediator of inflammatory responses in PAH37. In vascular
SMCs miR-181a inhibits angiotensin II signalling, the adhesion of
vascular SMCs to collagen and the expression of α-smooth muscle
cell actin, suggesting that miR-181 may negatively modulate
proliferative and migratory behaviour of HPASMCs in PAH38.
We observed contemporaneous, opposing changes in the expres-
sion of miR-181 and its target, Notch4, in the remodelled lungs of
human PAH patients and Sugen/hypoxia mice. Notch4 pre-
dominantly localises to the vascular endothelium and regulates cell
apoptosis, proliferation and VEGF-driven angiogenesis39,40. Its
expression is increased by VEGF and FGF, both abundant in the
remodelled PAH lung3,41. Expression of Notch 1–4 is elevated in
the remodelled lungs of hypoxic rats, with Notch4 mRNA
showing the highest (fivefold) increase42. Consistent with this, we
found that the levels of Notch4 mRNA were significantly elevated
in blood-derived IPAH ECFCs, in the plexiform lesions in IPAH
lungs41 and in the remodelled lung tissues from HPAH patients
with a KLF2 mutation.
miR-324 controls proliferation, angiogenesis and oxygen
metabolism in cells. We noted that miR-324 expression was sig-
nificantly reduced, while expression of its key target, transcription
factor ETS-1, was increased in ECFCs from IPAH patients, lung
tissues from IPAH and HPAH patients and lungs from Sugen/
hypoxia mice. ETS-1 activation is associated with expansive cell
proliferation; high expression levels of ETS-1 facilitate the invasive
behaviour of tumour cells and are predictive of the poor prognosis
in multiple types of carcinoma43. ETS-1 also regulates VEGF-
induced transcriptional responses44, increases endothelial angio-
genesis, extracellular matrix remodelling and the expression of
glycolytic enzymes and associated feeder pathways45, known to
augment vascular remodelling in PAH46,47.
miR-181 and miR-324 may also exert their effects by altering
post-translational modification of proteins via O-linked (on Ser/
Thr) or N-linked attachment (on Asn) of GlcNAc or via attach-
ment of GlcNAc onto fucose residues on the Notch receptors,
essential for their activation and ligand specificity48. While O-
GlcNAcylation is required for vascular adaptation to stress con-
ditions, a chronic response has been linked to vascular injury and
increased vasoconstrictor/reduced vasodilator responses in cardi-
ovascular diseases, including arterial hypertension49,50.
ECFCs from IPAH patients display many of cellular abnorm-
alities associated with the disease, including hyperproliferation,
mitochondrial dysfunction and impaired ability to form vascular
networks, reflective of the exaggerated repair processes in the
remodelled lung. We observed that proliferative and angiogenic
responses of IPAH ECFCs were reduced by overexpression of
miR-181 and miR-324 and by silencing of Notch4 and ETS-1.
Homoeostatic effects of KLF2 exosomes are likely to result
from the cumulative reduction in expression of multiple targets of
miR-181 and miR-324. Considering that miRNAs regulate the
expression levels of multiple genes simultaneously and often
cooperatively11, delineating individual contributions of miR-181
and miR-324 gene targets is beyond the scope of this investigation.
The mechanism through which KLF2 upregulates expression of
miR-181 and miR-324 is unknown and may involve interaction of
KLF2 with promoter or enhancer regions of target miRNAs,
indirect transcriptional regulation by intermediate agents or CpG
demethylation factors resulting in hypomethylation of pri-miRNA
promoters or post-transcriptional processes51–53.
KLF2 encourages selective sorting of miRNAs into exosomes54
and our data indicate that miR-181a-5p and miR-324-5p are
actively exported by the cells. Although the mechanism of miRNA
sorting is not well understood12, specific consensus sequence
motifs (EXOmotifs) have been implicated55. miR-181a-5p has two
EXOmotifs that differ from consensus sequence in one nucleotide
(GGAC, UGAC), while miR-324-5p shows three motifs, one with
perfect match to consensus sequence (CCCU) and two showing
alteration in one nucleotide (UCCG, GGAC).
Mechanisms responsible for the reduction in KLF2 expression
and signalling in PAH may involve genetic modification4, dysre-
gulation of BMPR2 function4 or inflammation56. Loss of nuclear
localisation as well as anti-inflammatory and anti-proliferative
properties of p.H288Y KLF2 mutant suggests that this genetic
modification is likely to exacerbate endothelial dysfunction in
patients. Inhibition of KLF2 signalling is likely to result in mala-
daptive responses to flow and endothelial damage57. Interestingly,
endothelial cells isolated from the subpleural lung microcircula-
tion of patients with PAH at the time of transplantation or
necropsy and submitted to ex vivo high shear stress exhibit
delayed morphological adaptation, compared with controls58.
While endothelial KLF2 and endothelium-derived KLF2-induced
miRNAs have homoeostatic, anti-proliferative effect on vascular
endothelial and smooth muscle cells, direct activation of KLF2 in
vascular smooth muscle cells does not restrict cell proliferation,
reflective of complex roles of KLF2 in the vasculature59.
In summary, we show that homoeostatic effects attributed to
endothelial KLF260 and laminar shear stress6 can be mimicked by
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KLF2-induced endothelial exosomal miRNAs. This study pro-
vides evidence of dysregulated KLF2 signalling in PAH and
highlights the potential therapeutic role of KLF2-regulated exo-
somal miRNAs in PH and other diseases associated with endo-
thelial damage, inflammation, proliferation and propensity for
vascular cell enlargement.
Methods
Endothelial and smooth muscle cell culture. HPAECs (PromoCell, C-12241)
were cultured in endothelial cell growth medium 2 (ECGM2; PromoCell, C-22111)
in polystyrene 75 cm2 culture flasks (Sarstedt, Germany) coated with 10 mg/L
solution of bovine plasma fibronectin (Sigma F1141) in PBS. Alternatively, the cells
were cultured in 96-well cell culture plates (Sarstedt; 10,000 cells per well) or on
fibronectin-coated Thermanox® Plastic Coverslips (13 mm; Thermo Scientific, UK,
174950) in a 24-well plate (Sarstedt; 50,000 cells per well, respectively).
HPASMCs (Lonza, CC-2581) were cultured in 75 cm2 tissue culture flasks in
smooth muscle cell growth medium 2 (SMCGM2, PromoCell, C-22062),
supplemented with 5% FCS and growth factor supplement (PromoCell, C-39267)
containing EGF (0.5 ng/mL), Basic FGF (2 ng/mL), insulin (5 μg/mL), and 1%
streptomycin and penicillin (100 μg/mL, ThermoFisher, 15070063). Only actively
growing cells (~48-h population doubling time), showing morphology typical for
endothelial cells (cobblestone when confluent, VE-cadherin+) or smooth muscle
cells (elongated, mesenchymal, α-SMA+), were used for experiments.
The cells were cultured under normoxic conditions in a humidified incubator
(37 °C, 20% O2, 5% CO2) until 80% confluency and were used between passages 4
and 10. In some experiments, the cells were incubated with human recombinant
TNF-α (R&D, 210-TA-020; 10 µg/L), VEGF165 (R&D, 293-VE; 50 ng/mL) or
exposed to hypoxia (5% CO2, 2% O2) for 24–72 h.
For non-contact co-culture of HPAECs and HPASMCs, 6.5, 12 and 24 mm
Transwell dishes with 0.4 μm pore polyester membrane inserts (Scientific
Laboratory Supplies, UK, 3470, 3460, and 3450) were used. The semi-permeable
membrane in Transwell insets allows exchange of exosomes between the two cell
types16. HPAECs were seeded into the fibronectin-coated top chambers inserted
into a 24-, 12- or 6-well Transwell dish at 30,000, 100,000 and 200,000 cells per
well, respectively and cultured in complete ECGM2 medium, whereas HPASMCs
were seeded at the bottom of a 24-, 12- or 6-well plate (50,000, 100,000 and 200,000
cells per well, respectively) and cultured in complete SMCGM2 for 24 h. The two
cell types were then washed with PBS, combined together and co-cultured in
endothelial cell basal medium supplemented with 10% FBS (Sigma-Aldrich,
F7524), and selected components of ECGM2 supplement pack (PromoCell, C-
22111): EGF (2.5 ng/L), FGF (10 ng/L), IGF (20 ng/L) with 1% penicillin and
streptomycin.
Patient-derived endothelial cells and lung samples. All investigations were
conducted in accordance with the Declaration of Helsinki. Venous blood samples
were obtained with the approval of the Brompton Harefield & NHLI and Ham-
mersmith Hospitals Research Ethics committees and informed written consent
from healthy volunteers (n= 14) and patients with IPAH (n= 12). Participants
were identified by number. Demographic and clinical features of healthy subjects
and patients are shown in the Table S6. Human endothelial colony forming cells
(ECFCs) were derived from peripheral blood samples61. Venous blood samples
(~50 mL) were collected in EDTA vacutainers, diluted 1:1 with phosphate-buffered
saline (PBS) containing 0.2% EDTA and 2% foetal bovine serum (FBS) and layered
onto Ficoll Plaque PLUS (GE Healthcare, Amersham, UK) for density gradient
centrifugation. Peripheral blood monuclear cells (MNCs) were aspirated, washed in
PBS and re-suspended in EGM-2 medium (CC-3156; Lonza Biologics, Slough,
UK), supplemented with growth factors (CC-4176, EGM™-2 bullet kit, Lonza), 20%
FBS (HyClone, Thermo Scientific, South Logan, UT, USA) and 1% antibiotic and
antimycotic solution (Gibco, Invitrogen, Paisley, UK).
Cells were seeded (3–5 × 107 MNCs in 4 mL of medium per well) in six-well
plates coated with type 1 rat tail collagen (BD Biosciences, Bedford, MA, USA). The
medium was replaced daily for the first week (removing non-adherent cells), and
every 2 days thereafter. Individual colonies were harvested by attaching a cloning
cylinder (8 or 10 mm in diameter; Millipore, Watford, UK) with vacuum grease
and using warm 0.05% TrypsinEDTA solution (Invitrogen) to remove all the cells
within the cylinder. Dislodged cells were re-suspended in fresh EGM-2 medium,
seeded (3000–5000 cells per cm2) in 1% gelatin precoated culture vessels and
propagated when 70–80% confluent. Distinct colonies of cells, capable of serial
propagation for at least eight serial passages and clonal growth, and displaying a
stable population doubling time as well as endothelial phenotype, were used
between passages 4 to 7. Endothelial cell lineage was confirmed with specific
markers, FITC-conjugated Ulex europaeus agglutinin-1 (UEA-1) lectin, mouse
monoclonal anti-human CD31 (JC/70 A, Dako, Glostrup, Denmark), anti-human
VE-Cadherin (sc-9989, Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit
polyclonal anti-human von Willebrand factor (A0082, Dako)61, with Alexa-488
green-conjugated secondary antibodies (Dako). A three-colour FACSCalibur flow
cytometer and CellQuest Pro software (BD Biosciences, Oxford, UK) were used to
analyse the stained cells by flow cytometry61.
Surgical samples of lung tissue were acquired from PAH patients at lung
transplantation (n= 6). Control tissues (n= 6) comprised uninvolved regions of
lobectomy specimens from patients undergoing surgery for bronchial carcinoma.
Tissues were transported on ice, and samples for protein extraction were snap-
frozen between 0.5 and 4.0 h before being stored at −80 °C until further analysis;
transport times for both control and PAH samples were similar. Lung lysates were
prepared as described in ref. 62. Briefly, lung samples (~200 mg) were added to an
ice-cold solution of 1 mL 100 mM phosphate buffer (pH 7.4), containing 1 mM
ethylenediamine tetraacetic acid and 1 mM L-dithiothreitol then homogenised for
1 min using PT-K Polytron® Stand Homogenizer (Kinematica AG, Lucerne,
Switzerland). Samples were kept on ice throughout the procedure (no protease
inhibitors were added) and frozen at −80 °C in aliquots of 0.1 mL until analysed.
Clinical information is shown in Supplementary Tables 6 and 7.
Adenoviral gene transfer. HPAECs or HPASMCs (80–90% confluent) were
infected with adenoviruses adeno-GFP (Adcontrol; Vector Biolabs, 1060) or adeno-
KLF2-GFP (AdKLF2; Vector Biolabs, ADV-213187) at the multiplicity of infection
(MOI) 1:100 or 1:250, respectively. Three hours later, media were changed and
some cells were treated with TNF-α (R&D, 210-TA-020; 10 µg/L), VEGF165 (R&D,
293-VE; 50 ng/mL) or exposed to hypoxia (5% CO2, 2% O2) for 24 h.
Immunofluorescence of cultured cells. To stain KLF2, cells grown on coverslips
were fixed with 4% formaldehyde, permeabilised with 0.1% Triton X-100 (Sigma-
Aldrich, 9002-93-1) and then incubated with methanol at −20 °C for 5 min. After
blocking in 2% bovine serum albumin (BSA) (Sigma-Aldrich, A2058) for 15 min,
the cells were incubated with mouse monoclonal anti-KLF-2 antibody (Novus
Biologicals, NB100-1051; 1:1000) and then FITC-Goat Anti-Mouse IgG (Jackson
ImmunoResearch Inc.,115-095-003; 1:200), and F-actin was visualised with
1 µg/mL TRITC-phalloidin (P1951; Sigma). Following immunostaining, cells were
mounted in Vectashield Antifade Mounting Medium containing nuclear stain
DAPI (Vector Laboratories, H-1200) and examined under the fluorescent confocal
microscope (Leica, TCS SP5, Leica Biosystems, Bretton, Peterborough).
Exosome purification and quantification. Exosomes were isolated from condi-
tioned media of HPAECs overexpressing AdGFP or AdKLF2-GFP cultured in
ECGM2 medium supplemented with 2% exosome-depleted serum (Thermo Fisher
Scientific, A2720801). Exosomes were isolated from 10 mL of conditioned media
24 h post-infection using miRCURYTM Exosome Isolation kit (Exiqon; 300102),
according to the manufacturer’s protocol (http://www.exiqon.com/ls/Documents/
Scientific/exosome-kit-cells-urine-csf-manual.pdf). Briefly, 4 mL of precipitation
buffer was added to 10 mL of conditioned culture media and incubated for 60 min
on a rolling shaker at 4 °C. After that, the media were spun for 30 min at 3200 × g at
20 °C and the resultant exosome pellet was re-hydrated in 200 μL of re-suspension
buffer, sonicated for a few seconds on ice and stored at −20 °C. The NanoSight
LM10 Particle Size Analyzer and Particle Counter (Malvern Instruments Ltd) was
used to track, analyse and obtain the size distribution and concentration mea-
surement of exosomes in liquid suspension. The presence of exosome membrane
markers was confirmed by western blotting and exosome marker microarray
analysis.
To check if exosome fractions collected from cells overexpressing AdKLF2-GFP
contain live viruses capable of inducing KLF2 expression in recipient cells, serial
dilutions of purified exosome fractions (10−1–10−7) were prepared in Dulbecco’s
Modified culture medium (Gibco, 1013-021) containing 2% FCS and incubated with
1.5 × 103 HEK293A cell (ThermoFisher Scientific, R70507) per well in 96-well plates.
The infected cells expressing GFP were identified by microscopic examination 48 h
later. Plaque formation was scored in 10 wells per dilution following 10-day
incubation. The TCID50 (Median Tissue Culture Infectious Dose) was calculated
according to the following formula based on the Sperman–Karber method (Hillar
Kangro Brian Mahy, Virology Methods Manual 1st Edition; eBook ISBN:
9780080543581; Academic Press 1996):
LogTCID50= highest dilution giving 100% CPE+ 0.25–0.5 (total no wells with
cpe per 10).
For experiments with HPAECs, the purified exosome fraction was further
diluted 50-fold in culture media and 24 h later KLF2 expression in cells was
measured by western blotting. Membranes were probed with a rabbit polyclonal
KLF-2 antibody (1:1000, Abcam, ab203591) and mouse monoclonal antibody
against β-actin (Sigma, A2228, 1:10,000 dilution). Secondary antibodies used were
HRP-linked goat anti-rabbit IgG (Sigma-Aldrich, A6154; 1:3000) and HRP-linked
sheep anti-mouse IgG (GE Healthcare Life Sciences, NAG31V; 1:2000). KLF2
peptide (US Biological, K1891-37p) was used as a positive control.
Western blot analysis of exosome marker proteins. Protein content in exosome
fractions was measured with a Pierce BCA Protein Assay Kit (Thermo Scientific).
Exosome samples in sample buffer were loaded onto 10% SDS/PAGE gels (10 μg
protein per lane) and subjected to electrophoresis followed by western blotting. The
membranes were probed for three different exosome markers: cluster differentia-
tion protein 63 (CD36), heat-shock protein 70 kDa (HSP70) and tumour sus-
ceptibility gene 101 (TSG101) with primary antibodies: mouse monoclonal anti-
CD63 antibody (E-12) (Santa Cruz; sc-365604; 200 μg/mL); mouse monoclonal
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anti-HSP 70 antibody (6D444) (Santa Cruz; sc-71278; 200 μg/mL); mouse mono-
clonal anti-TSG101 clone 51/TSG101 (RUO) antibody (BD Transduction
Laboratories; 612696; 250 μg/mL). HRP-linked Goat Anti-Rabbit IgG (Sigma-
Aldrich, A6154; 1:3000) and HRP-linked Sheep Anti-Mouse IgG (GE Healthcare
Life Sciences, Cat. No. NAG31V; 1:2000) were used as secondary antibodies.
Bands were visualised using Luminata Crescendo Western HRP Substrate
(Millipore) in a ChemiDoc™ Imager (Bio-Rad). The relative intensity of the
immunoreactive bands was determined by densitometry using Image J software.
Exosome array analysis. Purity of exosome fraction was also studied with exosome
array analysis (System Biosciences, EXORAY-4) which includes eight different types
of antibodies directed against exosome markers: FLOT1, ICAM, ALIX, CD81, CD63,
EpCAM, ANXA5 and TSG101, according to the manufacturer’s protocol (https://
www.systembio.com/downloads/Manual_EXAB__EXORAY_EXEL_WEB.pdf).
Transmission electron microscopy. For electron microscopy, adenovirus-infected
HPAECs (24 h post-infection) cultured on coverslips were fixed overnight at 4 °C
in 2–5% gluteraldehyde in 0.1 m Sörensen’s phosphate buffer (pH 7.4), postfixed
for 2 h at room temperature in 1% osmium tetroxide and dehydrated with
increasing concentration of ethanol before embedding in Araldite II resin.
Transversally cut sections were stained with uranyl acetate and lead citrate, and
viewed on a transmission electron microscope, Tecnai12 Biotwin with LAB6 fila-
ment, using a 2K Eagle CMOS camera. Images were acquired at 120 kV with
100 μm C2 aperture at spot size 6.
Cell treatment with exosomes and exosome internalisation. Exosomes were
purified from 10 mL of conditioned medium, providing the total of 4.12 ± 0.13 ×
1011 particles. Exosomal pellet was re-suspended in ECGM2 and approximately
2 × 105 exosomes per cell were added to HPAECs grown in 96- or 24-well dishes
and incubated for 24 h. To visualise the internalised exosomes, exosomal cell
membrane was stained with PKH26 Red Fluorescent Cell Membrane Linker Kit
(Sigma-Aldrich; PKH26GL-1KT), prior to the addition of exosomes to the cells,
according to the manufacturer’s protocol (http://www.sigmaaldrich.com/content/
dam/sigma-aldrich/docs/Sigma/Bulletin/pkh26glbul.pdf).
Briefly, following incubation with PKH26, the exosomes were washed three
times with PBS by ultracentrifugation at 100,000 × g for 10 min at 4 °C to remove
the unbound stain, and were seeded onto endothelial cells cultured on plastic
coverslips in 24-well dishes. Following 2 h incubation at 37 °C, the cells were fixed
in 4% formaldehyde and permeabilised with 0.1% Triton X-100 in PBS. The cells
were then incubated with 1 μg/mL FITC-phalloidin (P5282; Sigma) to visualise
filamentous actin, washed 3× in PBS and the coverslips were mounted in
Vectashield with DAPI. The cells were visualised under the Leica TCS SP5
Confocal Microscope with the objective ×63.
To visualise exosomal distribution in vivo, single injection of PKH26-labelled
exosomes63 (~2 × 1011 particles in 100 µL of PBS) in healthy mice was used to follow
distribution of exosomes in lungs, heart, liver and kidney 4 h post-injection. Lungs,
livers and kidneys were collected, fixed, paraffin embedded, cut into sections and
stained for von Willebrand Factor (vWF) or H&E. Localisation of the fluorescent
mimic to the endothelium was confirmed by co-immunostaining for vWF.
Universal RT microRNA PCR Human panel I+II. miRNA profile in HPAECs
overexpressing AdGFP (controls) and AdKLF2-GFP was analysed with Exiqon
miRCURY LNATM Universal RT (microRNA PCR Human panel I+II). The
universal RT microRNA PCR was performed on three exosome fractions per group
in two groups: (1) control (AdGFP-overexpressing) HPAECs and (2) HPAECs
showing ~3-fold increase in AdKLF2-GFP increase in expression.
All experiments were conducted at Exiqon Services, Denmark. Exosomes were
lysed in 700 μL QIAzol Lysis Reagent (Qiagen) in a Qiagen TissueLyzer with one
5 mm stainless steel bead. The lysate was transferred to a new tube with 140 μL
chloroform, mixed, incubated for 2 min at room temperature and centrifuged at
12,000 × g for 15 min at 4 °C. The upper aqueous phase was transferred to a new
tube and 1.5 volume of 100% ethanol was added. The contents were mixed gently,
transferred to a Qiagen RNeasy® Mini spin column, and total RNA was extracted
from the exosomes using the miRNeasy® Mini Kit (Qiagen) following the
manufacturer’s instructions. The RNA was eluted in 50 μL of RNase-free water and
stored at −80 °C until analysed.
Nineteen microliters of RNA were reverse transcribed in 95 μL reactions using
the miRCURY LNATM Universal RT microRNA PCR, Polyadenylation and cDNA
synthesis kit (Exiqon). cDNA was diluted 50× and assayed in 10 µL PCR reactions
according to the manufacturer’s protocol. Each microRNA was assayed once by
qPCR on the microRNA Ready-to-Use PCR, Human panel I+II using ExiLENT
SYBR® Green master mix. A “no template” sample in the RT step was included as a
negative control and profiled like the samples. The amplification was performed in
a LightCycler® 480 Real-Time PCR System (Roche) in 384-well plates. The
amplification curves were analysed using the Roche LC software, both for
determination of Cq and for melting curve analysis.
To ensure that the quality of the input RNA, the RNA spike-in kit (Exiqon) was
used. The RNA isolation controls (UniSp2, UniSp4 and UniSp5) were added
during the purification step to detect any differences in extraction efficiency,
whereas the cDNA synthesis control (UniSp6) was added in the reverse
transcription reaction. In addition, a DNA spike-in (UniSp3) consisting of a
premixed combination of DNA template and primers was add to all panels.
The amplification efficiency was calculated using algorithms similar to the
LinReg software. All assays were inspected for distinct melting curves and the Tm
was checked to be within known specifications for the assay. To be included in the
further analysis, assays had to be detected with 5 Cqs less than the negative control.
The upper limit of detection was set to Cq= 37. Cq was calculated as the second
derivative. All data were normalised to the average of assays detected in all samples
(n= 9)64.
The list of KLF2-induced miRNAs was then compared with the published lists
of differentially expressed miRNAs in PAH patients and PH animals15,23 using
Ingenuity Pathway Analysis software (IPA, Qiagen). miRNAs that were reduced in
severe PAH but significantly elevated by KLF2 were selected for further analysis.
Cell transfection. Transfection of miRNA mimics and inhibitors was carried out
with Lipofectamine RNAiMAX Transfection Reagent, according to the manu-
facturer’s instructions (Thermo Fisher, 13778150). To select endothelium-
protective exosomal miRNAs of potential therapeutic importance in PAH,
HPAECs were left untreated (control) or were transfected with control miRNA
(non-targeting transfection control; Ambion Life Technologies, 4464076) or let-7a-
5p (ID MC10050), miR-10a-5p (ID MC10787), miR-125b-5p (ID MC10148), miR-
181a-5p (ID MC10421), miR-191-5p (ID MC11717), miR-30a-3p (ID MC10611),
miR-30c-5p (ID MC11060), miR-324-5p (ID MC10253) at a concentration of
10 nmol/L (all miRVanaTM miRNA mimic, 4464066; Ambion Life Technologies).
Cy3 dye-labelled Pre-miR Negative Control (10 nmol/L; Ambion, AM17120) was
used to assess transfection efficiency.
In following experiments, HPAECs were left untreated or were transfected with
control miRNA at 20 nmol/L or control miR (10 nmol/L) plus either miR-181a-5p
(10 nmol/L; miRVanaTM miRNA mimic, 4464066, ID MC10421; miRVanaTM
miRNA inhibitor, 4464084, ID MH10421) or miR-324-5p (10 nmol/L; miRVanaTM
miRNA mimic, 4464066, ID MC10253; miRVanaTM miRNA inhibitor, 4464084,
ID MH10253) or a combination of miR-181 and miR-324 together (10 nmol/L of
each miRNA).
After 5 h, the media were changed and cells were exposed to hypoxia or treated
with TNF-α for 24–72 h. Alternatively, on the following day, the untransfected and
transfected cells were starved for 9 h before caspase 3/7 assay.
Transfection of cells grown in 24-well dishes with 20 pmol of Silencer Select
negative control #1 (Ambion, 4390843), Silencer Select ETS-1 siRNA (Ambion,
432420, ID: S4847) and Silencer Select Notch4 siRNA (Ambion, 4392420, ID:
S9643) or siETS-1 and siNotch4 in combination (10 pmol each) diluted in Opti-
MEM® I Reduced Serum Medium (Invitrogen, Cat. No. 31985-062) was carried out
with Lipofectamine RNAiMAX Transfection Reagent as previously described. The
cells were used for experiments 24–48 h post-transfection. Silencing of KLF4 was
carried out with Silencer Select KLF4 siRNA (Ambion, 4392420, ID: S17793). Cell
proliferation and NFκB activity assays were carried out 48 h post-transfection.
Lentiviral overexpression of KLF2 c.862C>T p.H288Y mutant. Lentiviral con-
structs for KLF2 overexpression were generated as described in ref. 29. Human KLF2
ORF was generated by PCR from SC127849 cDNA (Origene) using KLF2_EcoRI_
FLAG85F CTAGGAATTCGCCACCATGGACTACAAAGACGATGACGACAAG
ATGGCGCTGAGTGAACCCAT and KLF2_XhoI_1152R CTAGCTCGAGCTACA
TGTGCCGTTTCATGTGC primers, tagged at the N-terminal with flag, and cloned
into EcoRI/XhoI sites of pENTR1A no ccdB vector. Mutagenesis of wild-type KLF2
was performed using QuickChange® II Site-Directed Mutagenesis kit (Stratagene),
according to the manufacturer’s instructions KLF2_C862T_F CAAGAGTTCGTAT
CTGAAGGCGCA; KLF2_C862T_R TGCGCCTTCAGATACGAACTCTTG). Wild
type and mutant flag-tagged KLF2 were verified by Sanger sequencing and recom-
bined into lentiviral vector pLenti CMV/TO GFP-Zeo DEST (Addgene 17431).
To produce lentiviral stocks, 70% confluent HEK293FT (Invitrogen, cat. R700-07)
cells grown in T175 cm2 flasks (1 flask per lentiviral preparation), were transfected
with packaging plasmids by adding a mix of pMDLg/pRRE (11 µg; Addgene 12251),
pRSV-Rev (5.2 µg; Addgene 12253), pMD2.G (7.2 µg; Addgene 12259) and pLenti
CMV/TO GFP-Zeo KLF2_C862T (16 µg) dissolved in 1mL OptiMEM, and 20mL of
PEIpro DNA transfection reagent (VWR, 115-010). Next day, cell medium was
replaced with 20mL of fresh DMEM medium containing 10% FBS supplemented
with 0.1mM MEM non-essential amino acids, 1 mM sodium pyruvate and 2mM
L-glutamine without antibiotics. Lentiviral particles were harvested 48 h later, passed
through Steriflip-HV 0.45 µm PVDF filter (Millipore, SE1M003M00). Twenty
microliters DNase (1mg/mL) (1:1000) and 20 µL MgCl2 (1M) (1:1000) were added to
lentiviral supernantant, mixed by inversion, incubated at 37 °C for 20min and then
incubated overnight at 4 °C with 6mL of Concentrator-X (631232, Takara). Next day,
the mixture was spun at 1500g at 4 °C and the pellet was resuspended in 200 µL,
aliquoted and stored at −80 °C.
HPAECs were incubated with lentiviral particles carrying WT KLF2 or KLF2
variant c.862C>T.
To achieve inducible KLF2 expression, HPAECs were incubated with lentiviral
particles carrying WT KLF2 or KLF2 variant c.862C>T. KLF2 expression was
induced by doxycycline (1 µg/mL) and measured by RT-qPCR at 72 h. Cells were
used for experiments 72 h post-transduction.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14966-x ARTICLE
NATURE COMMUNICATIONS | (2020)11:1185 | https://doi.org/10.1038/s41467-020-14966-x | www.nature.com/naturecommunications 13
Exosomal miRNA transfer under flow. 6 × 103 cells in 100 µL ECGM2 medium
were seeded into each of six chambers of µ-Slide VI 0.4 (Ibidi, 80606). On the
following day, the cells grown in the first chamber were transfected with fluorescent
Cy3-miR (10 nmol/L; Ambion, AM17120) and washed several times before con-
necting the chamber to other two flow chambers in tandem, so that the medium
from chamber 1 would flow through chamber 2 and then chamber 3 and out. A
peristaltic pump (Ismatec REGLO ICC Digital Peristaltic Pump, Cole-Parmer)
created laminar flow of media over the endothelial cells at 4 or 10 dynes/cm2. Two
independent flow systems were set on one Ibidi slide (two sets of three chambers in
two separate flow circuits) and the experiment was repeated in triplicate.
Caspase 3/7 apoptosis assay. HPAECs grown in 96-well plates (10,000 cells per
well) were left untreated or were treated with exosomes, infected with AdGFP or
AdKLF2-GFP or were transfected with miRNA mimics or inhibitors. After an
overnight incubation HPAECs were left in full medium or were incubated in
serum- and growth factor-depleted medium for 9 h to induce apoptosis.
Apoptosis was measured using Cell MeterTM Caspase 3/7 Activity Apoptosis
Assay Kit (AAT Bioquest, ABD-22796). Fluorescence intensity, proportional to the
number of apoptotic cells, was analysed in GlomaxTM luminometer at Ex/Em=
490/525 nm.
NFκB luciferase reporter assay. HPAECs grown in 96-well black polystyrene
microplates with clear bottom (Corning, CLS3603) were infected with AdNFκB-luc
at the MOI 1:100 for 1 h. The cells were left untreated or were infected with AdGFP
(adenoviral control) or AdKLF2-GFP at the MOI 1:250 for 1 h, then the media was
changed and the cells were incubated for 24 h in normoxic or hypoxic conditions
(5% CO2, 2% O2) at 37 °C. In some experiments, the cells were transfected with
non-targeting transfection control or miR-181 or miR-324. TNF-α (10 µg/L) was
added to the cells 1 h after adenoviral infection and miRNA transfection and
incubated for 24 h. At the end of the experiment, the cells were lysed and lumi-
nescence was measured in Promega Luciferase Assay (Promega, E1500) in the
Glomax™ luminometer, according to the manufacturer’s instructions.
RNA extraction. RNA was extracted from trypsynised HPAECs or lung tissue
(~10 mg) using the miRCURYTM RNA Isolation Kit (Exiqon), according to the
manufacturer’s instructions. To remove any residual DNA that may affect down-
stream applications, an On-Column DNA Removal step was performed using the
RNase-free DNase Set (Qiagen). RNA concentration and purity was evaluated
using the NanoDrop 2000 spectrophotometer (Thermo Scientific). The A260/230 and
A260/280 ratios were used to assess the presence of contaminants. RNA was then
stored at −80 °C for later experiments.
Real-time quantitative PCR. Input RNA (50–100 ng/µL) was reverse-transcribed
using SuperScrip™ II Reverse Transcriptase (Invitrogen) or TaqMan MicroRNA
Reverse Transcription Kit (Thermo Fisher Scientific) and custom Multiplex RT
Primer pool in a SimpliAmp™ Thermal Cycler (Applied Biosystems), according to
the manufacturer’s instructions. The multiplex RT primer pool consisted of pri-
mers for miR-181a-5p, miR-324-5p, miR-32-5p and U6 (Thermo Fisher Scientific).
No-template samples were included as negative controls.
TaqMan® Gene Expression Assays for KLF2 (Hs00360439_g1, Mm00500486_
g1), KLF4 (Hs00358836_m1), NOTCH4 (Hs00965895_g1, Mm00440525_m1),
ETS1 (Hs00428293_m1, Mm01175819_m1), GAPDH (Hs02786624_g1, Mm99999
915_g1), TNF-α (Hs00174128_m1), MAPK18 (Hs00559623_m1) and TaqMan®
miRNA Assays for miR-181a-5p (Assay ID 000480), miR-324-5p (Assay ID
000539), miR-32-5p (Assay ID 002109) and U6 snRNA (Assay ID 001973), all
Thermo Fisher Scientific, were used to perform quantitative PCR (qPCR). No-
template samples were included as negative controls and all PCRs were performed
in triplicate. The reaction was performed on a QuantStudio 12K Flex Real-Time
PCR System (Applied Biosystems). Data were analysed using QuantStudio 12K
Flex Software version 1.2 (Applied Biosystems). For relative quantification, the data
were analysed using the 2−ΔΔCt method, where GAPDH and U6 snRNA were used
as endogenous normalisation controls for gene and miRNAs expression,
respectively. Additional information regarding TaqMan probes used in this study is
provided in Supplementary Table 8.
Luciferase reporter assays. Twenty nanograms of each luciferase reporter plas-
mids harbouring the 3′ UTR of Notch4 (ID HmiT011877; NM_004557.3), ETS-1
(ID HmiT062493; NM_001162422.1) and miRNA Target clone control vector for
pEZX-MT06 (negative control; CmiT000001-MT06), all from GeneCopoeia, Inc.
(Rockville, MD, USA), were co-transfected with control miRNA, miR-181a-5p or
miR-324-5p (Ambion Life Technologies) at 10 nmol/L using Lipofectamine
RNAiMAX Transfection Reagent (Thermo Fisher, 13778150) in 70% confluent
HPAECs grown in 24-well plates, according to the manufacturer’s instructions.
Luciferase activities were measured with Luc-Pair Duo-Luciferase HS Assay Kit 2.0
(GeneCopoeia, LF004) in a GlomaxTM luminometer (Promega) and were nor-
malised to Renilla luciferase activity.
Stimulation of KLF2 expression by shear stress. HPAECs were cultured in
9-cm2 Nunc® Lab-Tek™ Flaskettes® (VWR, 62407-340). The slides were detached
and inserted into flow chambers in a parallel chamber flow apparatus65. Endo-
thelial cells were subjected to laminar flow at 4 or 10 dynes/cm2 for 24 h. KLF2 and
miRNA expression levels in cells grown under the static and flow conditions were
measured by qPCR.
HPASMC EdU proliferation assay. Cell proliferation was studied with EdU Cell
Proliferation Assay Kit (EdU-594, EMD Millipore Corp, USA, 17-10527),
according to the manufacturer’s protocol. in total, 30,000 HPAECs were seeded
into the Transwell inserts, whereas 50,000 HPASMCs were seeded onto plastic
coverslips (Thermo Fisher Scientific, 174950) inserted into 24-well plate. HPAECs
were infected with Adcontrol or AdKLF2 and 3 h later the cells were transfected
with miRNA inhibitors or transfection controls. Next day, Transwell inserts with
HPAECs were placed in the wells containing HPASMCs and the two cell types
were co-cultured for further 72 h in normoxic or in hypoxic conditions. Twenty-
four hours before the end of the experiment, 10 µmol/L EdU was added to the cells.
At the end of the incubation period, the medium was removed, and the cells were
fixed in 3.7% formaldehyde solution (Fisher Scientific, F/1501/PB17) in PBS for
15 min at room temperature. After aspiration of the fixing solution, the cells were
washed twice with 3% BSA (Sigma-Aldrich, A3294) in PBS (Scientific Laboratory
Supplies, LZ51226) and permeabilised with 0.5% Triton X-100 (Sigma-Aldrich,
9002-93-1) for 20 min at room temperature. The cells were then washed twice
again with 3% BSA. Two hundred microliters of EdU reaction cocktail prepared
according to the manufacturer’s instructions were added to the wells. After 30 min
incubation in the dark at room temperature, reaction cocktail was removed, and
cells were washed three times with 3% BSA.
To visualise cell nuclei, 5 mM stock Nuclear Green DSC1 (Abcam, ab138905)
was diluted to 1:1000 in PBS and 200 μl of this solution were added to each well.
The cells were incubated for 1 h in the dark at room temperature and then washed
two times with PBS. The coverslips were then removed and mounted on a glass
slide (VWR, 6310107) in Vectashield® Antifade Mounting Medium (Vector
Laboratories, H-1000).
The cells were examined under a fluorescent microscope (Olympus IX70). EdU-
incorporating nuclei were visualised at Ex/Em 590/617 nm, while all nuclei stained
with Nuclear Green were visualised at Ex/Em 503/526 nm. Cell nuclei were
counted using ImageJ software with a macro designed by Steven Rothery (Facility
for Imaging by Light Microscopy, Department of Medicine, Imperial College
London, UK). Data are shown as fold-change in the percentage of EdU-
incorporating cells in hypoxia- or PDGF-treated cells, compared with untreated
controls.
To study the effect of endothelial KLF2-induced exosomes on PDGF-induced
HPASMC proliferation, HPAECs were seeded in a T-75 flask at 80% confluency
and transfected the day after with Adcontrol or AdKLF2, as previously described.
After transfection, 8 mL of growth factor- and heparin-free, serum-reduced (1%
exosome-depleted FBS) ECGM2 were added to each flask. To verify the role of
exosomes in the observed cell responses, HPAECs were pre-incubated with the
exosome release inhibitor GW4869 (10 µM, Sigma, D1692)25 for 8 h, before
treatment with adenoviruses. The cells were then incubated in 8 mL of EGGM2
medium in the presence of exosome GW4869. After 24 h, endothelial cell media
were collected, centrifuged for 5 min at 10,000g to remove cell debris, and stored at
−20 °C.
HPASMCs were seeded onto coverslips inserted into the wells of the 24-well
plate (50,000 cells per well) and cultured in normal SMCGM2 for 24 h. The
medium was removed, and the cells were starved for 2 h in serum- and growth
factor-free SMCGM2. Conditioned media from Adcontrol and AdKLF2-
overexpressing endothelial cells were defrosted, supplemented with 10 µM EdU,
with or without 10 ng/mL PDGF (Thermo Fisher Scientific, PHG0044) and
added to HPASMCs. EdU proliferation assay was performed, as previously
described.
HPAEC and ECFC EdU proliferation assay. HPAECs (untreated, treated with
exosomes, untransfected or transfected with control miRNA, miR-181, miR-324,
ETS-1 siRNA, Notch4 siRNA, as appropriate) were grown in 96-well black poly-
styrene microplates with clear bottom (Corning, CLS3603) at the cell density of
15,000 cells per well. The cells were pre-starved in growth factor-depleted EGM2
medium containing 2% FCS for 8 h. In all, 50 ng/mL of VEGF165 (R&D, 293-VE)
was added together with 10 µM EdU 18 h before the end of experiment.
ECFCs from healthy donors and IPAH patients were seeded into 96-well black
polystyrene microplates with clear bottom at the cell density of 15,000 cells per well
and cultured for 8 h in growth factor-free EGM-2 medium (CC-3156, Lonza
Biologics, Slough, UK), supplemented with 5% FBS (HyClone, Thermo Scientific,
South Logan, UT, USA) and 1% antibiotic and antimycotic solution (Gibco,
Invitrogen, Paisley, UK). Ten micromolar EdU was added to the cells and the cells
were incubated for further 18 h. HPAECs and ECFCs were then fixed and stained
as described in the EdU proliferation assay for HPASMCs. Instead of Nuclear
Green, in some experiments cell nuclei were labelled with 0.1 μg/mL Hoechst 33342
(Thermofisher, 62249) and detected at Ex/Em 361/421 nm.
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RNA-sequencing. Next-generation RNA sequencing of HPAECs transfected with
miR-181 or miR-324 with two biological replicates was performed at the Imperial
BRC Genomics Facility (Imperial College London, UK). RNA quality and quantity
were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies) and a
Qubit 4 Fluorometer (Thermo Fisher Scientific). RNA libraries were prepared using
TruSeq® Stranded mRNA HT Sample Prep Kit (Illumina Inc.) according to the
manufacturer’s protocol. Briefly, 1 µg of high-quality total RNA (RNA Integrity
Number Score ≥8.0) was used for polyadenylated RNA selection using poly-T oligo
attached magnetic beads, followed by the fragmentation of poly-A containing
mRNA. Cleaved RNA fragments were copied into first strand cDNA using reverse
transcriptase with random primers. The cDNA was further converted into double-
stranded DNA that was end-repaired to incorporate the specific index adapters for
multiplexing, followed by purification and amplification. The amplified libraries
were examined using an Agilent 2100 Bioanalyzer and a Qubit. The samples were
then pooled and run over four lanes (2 × 100 bp) on a HiSeq 2500 using TruSeq
SBS V3-HS kit (Illumina Inc.) in high output run mode. Average sequencing depth
across samples was 34.4 million reads.
Bioinformatics and data analyses. Sequence data were de-multiplexed using
bcl2fastq2 Conversion Software v2.18 (Illumina Inc.) and converted from BCL to
FASTQ file format. Base and sequencing quality, GC content, sequence length,
duplication, and adapter content were assessed using FastQC (available online at
http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Transcripts from
paired-end stranded RNA-Seq data were quantified with Salmon v0.8.2 using hg38
reference transcripts66. Count data were normalised to accommodate known batch
effects and library size using DESeq267,68. Pairwise differential expression analysis
was performed based on a model using the negative binomial distribution and
P values were adjusted for multiple test correction using the Benjamini–Hochberg
procedure27. Genes were considered differentially expressed if the adjusted P value
was greater than 0.05 and there was at least a 1.5-fold change in expression.
Enrichment analysis was performed using DAVID v6.8, Panther and Ingenuity
Pathway Analysis (IPA, Qiagen), where significant enrichment was determined if
the adjusted P value was >0.05. Network mapping of protein–protein interactions
was obtained using STRING v10.569.
Animal experiments. All animal experiments were conducted according to and in
compliance with the guidelines from Directive 2010/63/EU of the European Par-
liament for animal testing and research, with ethical approval from Imperial
College London under UK Home Office Licence number PPL 70/7989 and in
compliance with the UK Animals (Scientific Procedures) Act of 1986. All animals
were randomly allocated to groups, and all personnel involved in data collection
and analysis (haemodynamics and histopathologic measurements) were blinded to
the treatment status of each animal. Only weight- and age-matched males were
included for experimentation as, in contrast to the human clinical studies, most
animal studies have shown that female sex and oestrogen supplementation have a
protective effect against PAH.
Eight-week-old C57/BL male mice (20 g; Charles River, UK) were injected
subcutaneously with Sugen (SU5416; 20 mg/kg; Tocris Bioscience), suspended in
0.5% [w/v] carboxymethylcellulose sodium, 0.9% [w/v] sodium chloride, 0.4% [v/v]
polysorbate 80, 0.9% [v/v] benzyl alcohol in deionized water once per week.
Control mice received only vehicle. Mice were either housed in normal air or
placed in a normobaric hypoxic chamber (10% O2) for 3 weeks (n= 8 per group).
miR-181a-5p (ID MC10421) and miR-324-5p (ID MC10253) together, or
Negative Control 1 mirVana miRNA mimics In Vivo Ready (all from Ambion),
were complexed with Invivofectamine® 3.0 reagent (Invitrogen) and injected
intravenously twice a week at 2 mg/kg body weight.
At 3 weeks, the mice were removed from the hypoxic chamber and anaesthetised
by intraperitoneal injection of ketamine/dormitor (75+ 1 mg/kg). Development of
PH was verified as described previously70. RVSP was measured via direct cardiac
puncture using a closed-chest technique in the spontaneously breathing
anesthetized animal. The animals were then euthanized, the hearts were removed
and the individual ventricular chambers were weighed, and RVH was assessed as the
right ventricle to left ventricle to septum ratio (RV/LV+S). The right lungs were
snap-frozen in liquid nitrogen and stored at −80 °C for biochemical measurements
or placed in RNAlater® RNA Stabilisation Solution for RNA isolation. The left lungs
were fixed by inflation with 10% formalin, embedded in paraffin, and sectioned for
histology. Transverse formalin-fixed lung sections were stained with an anti-smooth
muscle actin antibody (Sigma) or Verhoeff’s van Gieson stain (EVG) to visualise
elastic lamina. Muscularisation of small intrapulmonary arteries was determined by
counting all muscularised vessels with a diameter smaller than 50 μm in each
section, and expressed as a % of all (muscularised+ non-muscularised) vessels.
Counting was performed by two blinded investigators.
A preliminary experiment was carried out to evaluate the effects of miR-181 and
miR-324 alone or in combination on NFĸB activation. Eight-week old C57/BL male
mice (20 g; Charles River, UK; n= 5 per group) were injected intravenously with
Negative Control 1, miR-181a-5p, miR-324-5p, or miR-181a-5p plus miR-324-5p,
as previously described. The day after the mice were injected subcutaneously with
Sugen or vehicle and either housed in normal air or placed in a normobaric hypoxic
chamber (10% O2) for 48 h for tissue collection.
Immunostaining. For ABC-peroxidase staining, dewaxed and rehydrated lung
sections were subjected to heat-induced antigen retrieval in 10mM sodium citrate
(pH 6.0), 0.05% Tween 20, at 80 °C for 10min, and immunostained using the avidin-
biotin-peroxidase complex (ABC Elite, Vector Laboratories) method and 3,3′-dia-
minobenzidine as a substrate (DAB Enhanced Liquid Substrate System; Sigma-
Aldrich). Sections were incubated with a mouse monoclonal anti-human smooth
muscle actin antibody (1:1000; M0851; Dako) and a biotinylated anti-mouse IgG
(1:100; BA-2000; Vector Laboratories) as a secondary antibody. Sections incubated
with purified non-immune rabbit IgG were used as staining controls. Slides where
mounted in DPX mountant for histology (Sigma-Aldrich), and analysed under the
under fluorescent confocal microscope (Leica, TCS SP5, Leica Biosystems).
Tissue homogenate preparation and western blotting analysis. Tissue samples
were homogenised in RIPA buffer (Sigma) for 1 min using PT-K Polytron® Stand
Homogenizer (Kinematica AG). Samples were kept on ice throughout the proce-
dure and frozen at −80 °C in aliquots of 0.1 mL until analysed. Protein content was
estimated using the bicinchoninic acid method (Thermo Fischer Scientific) with
bovine albumin as standard.
Proteins were separated by 4–12% NuPAGE® Bis-Tris gels (Invitrogen) using
MES buffer at 200 V constant for 35min (5 µg equivalent of protein per lane).
Membranes were probed with a mouse monoclonal antibody against β-actin (Sigma,
A2228, 1:10,000 dilution). Primary antibodies used in western blot analysis included
mouse monoclonal anti-β-actin (Sigma A2228, 1:3000), NOTCH4 (Santa Cruz, sc-
393893, 1:1000), ETS-1 (Santa Cruz, sc-55581, 1:1000), α-SMA (Sigma, A5228,
1:1000), human/mouse pSer536-p65 (Cell Signaling, 3033, 1:1000) and rabbit
polyclonal anti-PCNA (1:500, Santa Cruz Biotechnology, sc-7907). Secondary
antibodies were HRP-linked Goat Anti-Rabbit IgG (Sigma-Aldrich, A6154; 1:3000)
and HRP-linked Sheep Anti-Mouse IgG (GE Healthcare Life Sciences, NAG31V;
1:2000), rabbit anti-goat polyclonal antibody (R&D, HAF017, 1:3000).
Bands were visualised using Luminata Crescendo Western HRP Substrate) in a
ChemiDoc™ Imager. The relative intensity of the immunoreactive bands was
determined by densitometry using Image J software.
Nuclear translocation of p65NFκB. Nuclear translocation of p65 NFκB was
studied with Image J by measuring colocalization of nuclear stain DAPI with
p65NFκB stained with rabbit p-NFκB p65 (Ser 276) (Santa Cruz Biotechnology, sc-
101749; 1:200) and secondary antibody, TRITC-labelled goat anti-rabbit antibody
(Jackson ImmunoResearch Laboratories, 111-025-144, 1:200) in confocal images of
cells or lung sections. The white pixel area, marking nuclear NFκB, was used to
quantitate p65 NFκB translocation in cells and tissues.
RNAscope® in situ hybridisation. Histological sections of lung tissues from
treatment-naïve PAH patients at lung transplantation (n= 6), and control tissues
comprising uninvolved regions of lobectomy specimens from four patients under-
going surgery for bronchial carcinoma and two unused donor lungs were from the
tissue archives at Hammersmith Hospital, Imperial College London. Tissue samples
were fixed in 10% formal-saline and embedded in wax, and sections were processed
for immunohistochemistry. Sections from HPAH patients with c-terminal missense
mutation in KLF2 gene were obtained from three family members, father who died
aged 32 and his two daughters who underwent lung transplantation4. Lung sections
from healthy and Sugen/hypoxia mice were also used for the analysis.
For formalin-fixed, paraffin-embedded tissues FFPE tissues, RNAscope®
Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics) and TSATM
Cyanine 3 & 5, TMR, Fluorescein Evaluation Kit System (PerkinElmer) were used
according to the manufacturers’ protocols28.
Briefly, tissue sections of 5-µm thickness were baked in a dry oven (Agilent
G2545A Hybridisation Oven, Agilent Technologies) for 1 h at 60 °C, and
deparaffinised in xylene, followed by dehydration in 100% ethanol. Tissue sections
were then incubated with RNAscope® Hydrogen Peroxide for 10 min at room
temperature. After washing twice with distilled water, manual target retrieval was
performed boiling the sections (100 to 103 °C) in 1× Target Retrieval Reagents
using a hot plate for 15 min. Slides were then rinsed in deionized water, 100%
ethanol, and incubated with RNAscope® Protease Plus at 40 °C for 30 min in a
HybEZ hybridisation oven (Advanced Cell Diagnostics). Hybridisation with target
probes (human: Hs-ETS1-C1, NM_001143820.1; Hs-NOTCH4-C2, NM_004557.3;
Hs-KLF2-C3, NM_016270.2; mouse: Mm-ETS1-C1, NM_011808.2; Mm-
NOTCH4-C2, NM_010929.2; Mm-KLF2-C3, NM_008452.2) was carried out
incubating the slides at 40 °C for 2 h. Up to three different probes (C1–C3) were
multiplexed. After washing twice with Wash Buffer, slides were stored overnight in
5× SSC buffer (0.75 M NaCl, 0.075 M sodium citrate). The following day, the slides
were incubated at 40 °C with the following reagents: Amplifier 1 (30 min),
Amplifier 2 (30 min), Amplifier 3 (15 min); HRP-C1 (15 min), TSA® Plus
fluorophore for channel 1 (fluorescein, cyanine 3, or cyanine 5, PerkinElmer;
1:1000; 30 min), HRP blocker (15 min); HRP-C2 (15 min), TSA® Plus fluorophore
for channel 2 (30 min), HRP blocker (15 min); HRP-C3 (15 min), TSA® Plus
fluorophore for channel 3 (30 min), HRP blocker (15 min). After each
hybridisation step, slides were washed three times with Wash Buffer at room
temperature.
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In some experiments, RNAscope hybridisation was combined with
immunofluorescence. Tissue was blocked for 1 h at room temperature with 3%
normal horse serum (Vector Laboratories) in 1× PBS containing 0.1% bovine
serum albumin (Sigma-Aldrich), and 0.01% sodium azide (Sigma-Aldrich), and
then incubated with polyclonal rabbit antibody raised against human von
Willebrand Factor (1:500; A0082; Dako), monoclonal mouse anti-human smooth
muscle actin antibody (1:1000; Dako, M0851), or monoclonal rabbit anti-NFkB-
p65 (1:400; Cell Signaling Technology, D14E12) at 4 °C overnight. After three
washes in PBS, slides were incubated with fluorescently labelled FITC Goat Anti-
Rabbit (1:100; 111-095-003; Jackson ImmunoResearch Inc.), TRITC Goat Anti-
Rabbit (1:100; 111-025-003; Jackson ImmunoResearch Inc.), and TRITC Goat
Anti-Mouse IgG (1:100; T5393; Sigma-Aldrich) for 30 min at RT. Following
immunostaining, tissues were mounted in Vectashield with DAPI and examined
under a fluorescent confocal microscope (Leica, TCS SP5, Leica Biosystems,
Bretton, Peterborough).
Angiogenesis assay. Angiogenic responses were studied using matrigel tube for-
mation assay in ECFCs transfected with control (non-targeting) miRNA, miR-181
+324, control siRNA or Notch4 and ETS-1 siRNA. Briefly, 24 h post-transfection
the cells were trypsinized, re-suspended in growth factor-free media containing 5%
FBS and seeded at a density of 10,000 cells per well in 96-well plates coated with
30 µL Matrigel (BD Biosciences, 354230). Cells were fluorescently labelled with Cell
Tracker Green (ThermoFisher Scientific, C2925) following the manufacturer’s
protocol and examined under a fluorescent microscope Olympus IX70 with ×10
objective. Total tube length was determined using Image J software.
Statistics. All experiments were performed at least in triplicate and measurements
were taken from distinct samples. Data are presented as means ± s.e.m. Normality
of data distribution was assessed with Shapiro–Wilk test in GraphPad Prism 7.03.
Comparisons between two groups were made with Student’s t-test, whereas ≥3
groups were compared by use of ANOVA with Tukey’s post hoc test. Statistical
significance was accepted at P < 0.05.
Data availability
The RNA-sequencing data generated and analysed during this study are available in the
BioProject repository (BioProject ID PRJNA531359; BioSamples SAMN11357006,
SAMN11357007, SAMN11357008, SAMN11357009, SAMN11357010, SAMN11357011;
Accession numbers SRX5651141, SRX5651140, SRX5651139, SRX5651138, SRX5651143,
SRX5651142) at the following link: [https://www.ncbi.nlm.nih.gov/sra?
term=SRP191343].
All data generated or analysed during this study are included in this published article
(and its supplementary information files) or are available from the corresponding author
upon request.
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